



## ROB RODRIGUES

Partner

+55 21 3550 3723

+55 21 99813 4328

roberto.rodrigues@lickslegal.com

### PRACTICE AREAS

- Patents
- Copyright
- Trade Secrets & Regulatory
- Data Protection
- Licensing & Technology Transfer
- Internet, E-commerce & Software
- Food & Drug

### LANGUAGES

- Portuguese
- English
- Spanish

### BIOGRAPHY

Rob Rodrigues manages high-stakes business and intellectual property disputes in Brazil. He assists his clients in complex matters ranging from managing patent prosecution portfolios to enforcement and monetization. Rob is an experienced attorney and acted as lead counsel in several preliminary injunction proceedings and patent trials. In addition, Rob aids clients with transactions involving businesses in their portfolio. Mr. Rodrigues' litigation-oriented mindset adds value when managing cross border risks.

Rob is regularly recognized by leading publications, including The Legal 500 and IP Stars, with client sources describing him as "greatly skilled at advising on the most complex and high-profile M&A transactions," and noting that he "combines strong technical skills and a flair for complexity with commercial awareness, pragmatism and sound judgment." Rob earned an LLM from Stanford Law School, where he was Lead Editor of the Stanford Technology Law Review. He joined Licks Attorneys again in 2019 after working at Quinn Emanuel Urquhart & Sullivan, LLP in New York City. He has also published articles in technology law journals around the world and is currently an editor of the Kluwer Patent Blog.

### REPRESENTATIVE CASES

- Trial associate for biopharmaceutical company in patent enforcement against biosimilar companies;
- Associate for startup company in defense of abusive behavior action;
- Counsel for pharmaceutical company in an antitrust case involving sham litigation claims.

### PROFESSIONAL HIGHLIGHTS

- The Legal 500 - 'Recommended' Life Sciences Practice (2023, 2022);
- IP Stars - 'Notable Practitioner (2022, 2021);
- Leaders League - Life Sciences (2022);

- IP Stars - 'IP Star' Rising Star (2019);
- Quinn Emanuel Urquhart & Sullivan, LLP, foreign associate (2017-2018);
- Stanford Technology Law Review: lead editor;
- Hoover IP2 Summer Teaching Institute – Residential Scholarship (2017).

## AFFILIATIONS

- Brazilian Bar Association – Rio de Janeiro Section (OAB/RJ).

## EDUCATION

- Stanford Law School (LLM in Law, Science and Technology 2017);
- Bachelor of Laws (LL.B), Universidade Federal do Rio de Janeiro (2013).

## PUBLICATIONS

- Co-author: New Regulation of Cannabis-Based Drugs Coming Soon (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), November/December 2019).
- Miller, Shawn P. and Aravind, Ashwin and Bengfort, Bethany and De La Cerda, Clarisse and Dragoni, Matteo and Gibson, Kevin and Itai, Amit and Johnson, Charles and Kannappan, Deepa and Kehoe, Emily and Kim, Hyosang and Mladinich, Katherine and Pinho, Roberto and Polansky, John and Weissenberg, Brian, Who's Suing Us? Decoding Patent Plaintiffs since 2000 with the Stanford NPE Litigation Dataset (July 18, 2018). Stanford Technology Law Review, Vol. 21, No. 234, 2018.
- Enforcing pending patent applications in Brazil: a different approach to dealing with the backlog (12, 2017 publication description Oxford Journal of Intellectual Property Law & Practice)
- Co-author: "Gauging the Future of Biosimilars in Brazil: Looking Ahead after the Approval of the Monoclonal Remsima" (GEN Exclusives, 2015) (<http://www.genengnews.com/public/AnalysisAndInsight/item.aspx?id=77900537&a=false>).
- Co-author: "Patent Knowledge Share: Brazil" (The Patent Lawyer Magazine, September/October 2015).
- Co-author: "The Business of Immuno-Oncology" (<http://www.genengnews.com/gen-exclusives/the-business-of-immuno-oncology/77900600>).
- Author: "Brazil: Pharmacovigilance Risk in Evolving Biosimilar Regulation" (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), March/April 2015).

## ARTICLES

- [The Amazon in the Limelight: An Opportunity for Biotech in Brazil](#), Genetic Engineering & Biotechnology News, 2023;
- [Startup valuation e cuidado com ativos intelectuais](#), Valor Econômico, 2023;
- [Patenting antibody-related inventions in Brazil](#), IP Stars, 2023;
- [Indústria de genéricos usa prática ilegal no Brasil para alterar bulas e infringir patentes](#), Migalhas, 2022;
- [Biomedical R&D in Brazil: who owns IP rights?](#), The Legal 500, 2022;
- [German Federal Court opens door more document transparency patent cases](#), JUVE Patent, 2022;
- [Framework for Analysis of Venue Selection for Global Patent Litigation: Strategic Considerations](#), The Sedona Conference, 2022;
- [Biomedical Innovation in Brazil: an update](#), Bioengineering, 2022;
- [An overview of post-grant opposition procedure in Brazil](#), IP Stars, 2022;
- [How Brazil is becoming a more favourable jurisdiction for life sciences patentees](#), IAM, 2022;

- [Biotechnology/pharma patent litigation in Brazil: an update on preliminary injunctions](#), Kluwer Patent Blog, 2022;
- [Post-filing experimental evidence: how to obtain patents in Brazil?](#), Kluwer Patent Blog, 2022;
- [Brazil's patent term decision: impact and practical tips](#), IP Stars, 2021;
- [Brazilian Supreme Court considers ruling on patent case for the first time in this century](#), Journal of Intellectual Property Law & Practice, 2021;
- [Thousands of patents at risk of cancellation in Brazil](#), IAM, 2021;
- [Brazilian Supreme Court Sets an earlier date to decide the fate on the 10-Year Patent Term](#), BRICS and Beyond, 2021;
- [Em pedido ao STF, PGR mira Covid-19, mas acerta na economia nacional](#), JOTA, 2021;
- [A estreia da propriedade intelectual no STF: ADI 5529 e seus impactos sistêmicos](#), JOTA, 2020;
- [A lição chinesa para a inovação](#), Estadão, 2020;
- [Google: um monopólio global imbatível no mercado de buscas?](#), Estadão, 2020;
- [L'accès à ce contenu exclusif est réservé aux clients Lexis 360®](#), Lexis 360, 2020;
- [Breaking through asphalt](#), Bioengineering, 2018.